{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041987","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.365100+00:00","generated_at":"2026-06-07T23:34:13.607297+00:00","sec_items":["1.01","2.03","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"MIRA Pharma licenses Ketamir-2, gets $3M loan from MIRALOGX; appoints new director","bullets":["Exclusive license for Ketamir-2 (oral ketamine analog) in North America; $100k upfront, 8% royalties.","MIRALOGX provides $3M line of credit to fund Ketamir-2 IND development; 8% interest, one-year term.","MIRA issues warrant for 700k shares at $2.00 per share, exercisable through Nov 15, 2028.","Michael Jerman appointed to Board, Audit Committee, and Compensation Committee effective Nov 14, 2023.","DEA determined Ketamir-2 is not a controlled substance; potential for home self-administration."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041987","json":"https://secwatch.observer/filing/0001493152-23-041987.json","markdown":"https://secwatch.observer/filing/0001493152-23-041987.md","text":"https://secwatch.observer/filing/0001493152-23-041987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:34:13.607297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"653b4186b8115f8e40ae28b6f67c3f651b830df4","claim":"MIRA PHARMACEUTICALS, INC. incurred loan of up to $3.0 million with MIRALOGX at annual fixed rate of 8% maturing November 15, 2023.","evidence_excerpt":"On November 15, 2023, the Company entered into a Promissory Note and Loan Agreement (the \"Loan Agreement\") with MIRALOGX. Pursuant to the Loan Agreement, the Company may borrow up to $3.0 million from MIRALOGX to fund the development of licensed products under the License Agreement (the \"Loan\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $3.0 million"},{"label":"Counterparty","value":"MIRALOGX"},{"label":"Rate","value":"annual fixed rate of 8%"},{"label":"Maturity","value":"November 15, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"bf9f03e77d","claim":"Michael Jerman was appointed as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"On November 14, 2023, the Board of Directors of the Company increased the number of directors on the Board from 7 directors to 8 directors and unanimously approved the election and appointment of Mr. Michael Jerman to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0d4f6803fcf6214799b8072258f4cb8bf9bc1b29","claim":"MIRA PHARMACEUTICALS, INC. entered into Promissory Note and Loan Agreement with MIRALOGX, LLC valued at Up to $3.0 million borrowing capacity; interest at 8% per annum; one-year term; repayment due Novemb (effective 2023-11-15).","evidence_excerpt":"On November 15, 2023, the Company entered into a Promissory Note and Loan Agreement (the “Loan Agreement”) with MIRALOGX. Pursuant to the Loan Agreement, the Company may borrow up to $3.0 million from MIRALOGX to fund the development of licensed products under the License Agreement (the “Loan”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"MIRALOGX, LLC"},{"label":"Value","value":"Up to $3.0 million borrowing capacity; interest at 8% per annum; one-year term; repayment due Novemb"},{"label":"Effective","value":"2023-11-15"}],"fact_type":"material_agreement"},{"claim_id":"622c43091023a5f90caa326489ab08a28b12d046","claim":"MIRA PHARMACEUTICALS, INC. entered into Exclusive License Agreement with MIRALOGX, LLC valued at $100,000 upfront payment plus quarterly royalties of 8% of net sales and 8% of other revenue; issuan (effective 2023-11-15).","evidence_excerpt":"On November 15, 2023 (the “Effective Date”), MIRA Pharmaceuticals, Inc. (the “Company”) and MIRALOGX, LLC, a Florida limited liability company (“MIRALOGX”), entered into an exclusive license agreement (the “License Agreement”) to develop and commercialize a drug product containing 2-(2- chlorophenyl)-2-(methylamino) cyclopentan-1-one (sometimes referred to by the Parties as “M209” or “KETAMIR-2”) (“the Product”) as an active agent in North America.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"MIRALOGX, LLC"},{"label":"Value","value":"$100,000 upfront payment plus quarterly royalties of 8% of net sales and 8% of other revenue; issuan"},{"label":"Effective","value":"2023-11-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}